(Q39734840)

14 September 2017

title

A glimpse at the future of hepatitis C therapy: the INFORM trial (English)

1 reference

14 September 2017

Lei Y Lim

1

1 reference

14 September 2017

Paul Y Kwo

series ordinal

2

1 reference

14 September 2017

language of work or name

English

0 references

publication date

1 July 2011

1 reference

14 September 2017

1 reference

14 September 2017

volume

54

1 reference

14 September 2017

issue

1

1 reference

14 September 2017

page(s)

360-363

1 reference

Diagnosis, management, and treatment of hepatitis C: an update

14 September 2017

cites work

1 reference

An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus

21 January 2018

1 reference

An NS3 serine protease inhibitor abrogates replication of subgenomic hepatitis C virus RNA.

21 January 2018

1 reference

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

21 January 2018

1 reference

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

21 January 2018

1 reference

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

21 January 2018

1 reference

Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir

21 January 2018

1 reference

Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients

21 January 2018

1 reference

Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms

21 January 2018

1 reference

Structural biology of hepatitis C virus

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/HEP.24432

1 reference

14 September 2017

1 reference